Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | SELP | P16109 | 3/20 | 0.47 |
| ▸ | SELL | P14151 | 2/20 | 0.47 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8587542 | 0.98 | AKR1C1 (0.57) | AKR1C1ALDH1A1TSHRHPGDKMT2A | |
| SCHEMBL521247 | 0.97 | AKR1C1 (0.54) | AKR1C1ALDH1A1TSHRHPGDKMT2A | |
| SCHEMBL1465003 | 0.94 | KMT2A (0.50) | AKR1C1ALDH1A1TSHRHPGDKMT2A | |
| SCHEMBL21874215 | 0.87 | KDM1A (0.49) | AKR1C1ALDH1A1KMT2AMEN1OPRD1 | |
| SCHEMBL1626965 | 0.87 | ICMT (0.48) | ALDH1A1KMT2AMEN1OPRD1OPRM1 | |
| SCHEMBL4878231 | 0.87 | HCAR2 (0.46) | AKR1C1ALDH1A1KMT2AMEN1OPRD1 | |
| SCHEMBL30683829 | 0.86 | ADAM17 (0.53) | ALDH1A1TSHRHPGDKMT2AMEN1 | |
| SCHEMBL2846322 | 0.86 | ADAM17 (0.53) | ALDH1A1TSHRHPGDKMT2AMEN1 | |
| SCHEMBL5668891 | 0.85 | LMNA (0.65) | ALDH1A1KMT2AMEN1OPRD1SLC22A1 | |
| SCHEMBL8585754 | 0.85 | ADAM17 (0.52) | ALDH1A1TSHRHPGDKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220363662-A1 | COMPOUNDS AS LXR AGONISTS | Integral Biosciences Privated Limited (IN) | 2022-11-17 | — | — | US | disclosed |
| WO-2022224166-A1 | COMPOUNDS AS LXR AGONISTS | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2022-10-27 | — | — | WO | disclosed |
| EP-1165082-A4 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 2002-06-12 | — | — | EP | disclosed |
| US-6358956-B1 | IMIDAZOLYLALKYL-1-PIPERAZINE DERIVATIVES; FARNESYL-PROTEIN AND GERANYLGERANYL TRANSFERASE INHIBITORS; ANTICARCINOGENIC AGENTS | MERCK & CO., INC. | 2002-03-19 | — | — | US | disclosed |
| EP-1165082-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000051611-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2000-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363662-A1 | COMPOUNDS AS LXR AGONISTS | NR1H2, NR1H3, NR1H4 | AKR1C1 277/4885ALDH1A1 781/4885TSHR 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.